Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

IMPORTANCE: Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti–vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report clinical outcomes after intravitreous inje...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Ophthalmol
Main Authors: Enríquez, Ana Bety, Baumal, Caroline R., Crane, Ashley M., Witkin, Andre J., Lally, David R., Liang, Michelle C., Enríquez, José Ramón, Eichenbaum, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907988/
https://ncbi.nlm.nih.gov/pubmed/33630045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2020.7085
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados